{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.84","upperLimit":"0.94","value":"0.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy","id":"OG000","title":"Pet Positive (Per Patient)"}],"paramType":"NUMBER","populationDescription":"All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per patient basis. Per patient analyses included an evaluation of positive or negative for presence of localized prostate cancer (PCa).","reportingStatus":"POSTED","timeFrame":"1 month","title":"Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation","type":"PRIMARY","unitOfMeasure":"percentage of times value is true"}